Compare Main Street Capital Corporation (MAIN) vs Nuwellis Inc (NUWE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Main Street Capital Corporation vs Nuwellis Inc — how do they compare? Main Street Capital Corporation trades at $54.47 (market cap $5.07B), while Nuwellis Inc trades at $0.68 (market cap $2.20M). The key difference: Main Street Capital Corporation is far larger — about 2304.5× Nuwellis Inc's market cap, and Main Street Capital Corporation pays a 5.87% dividend while Nuwellis Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Main Street Capital Corporation for 88 Days and Nuwellis Inc for 26 Days on average.
| MAIN | NUWE | |
|---|---|---|
Market Cap | $5.07B | $2.20M |
Volume | 685,683 | 121,544 |
Sector | Financials | Health |
52-Week High | $64.60 | $146.65 |
52-Week Low | $49.63 | $0.68 |
Typical Hold Time | 88 Days | 26 Days |
Enterprise Value | $7.51B | -$1.52M |
Dividend Yield | 5.87% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Main Street Capital (MAIN) trades at $54.18, down 1.08% on the day, with a bearish technical signal from moving averages and oscillators. The company reported mixed quarterly earnings, beating in Q2 2026 but missing in Q1 2026, while maintaining strong profitability with an 80.77% net income margin. Recent news highlights MAIN's status as a top-tier BDC with a well-covered monthly dividend, though some analysts cite valuation concerns amid rising Treasury yields.
Outlook remains cautiously optimistic given MAIN's robust fundamentals and dividend track record, but near-term headwinds include earnings volatility and premium valuation risks. The stock offers income appeal with a 7.9%+ yield, yet investors face pressure from technical weakness and macroeconomic sensitivity.
NUWE trades at $0.6907, down 1.48% on the day, with a bearish technical signal from moving averages despite oversold RSI readings. The company reported revenue growth to $9M in 2026 but remains deeply unprofitable with a net income margin of -125.63%. Recent news highlights console sales growth and strategic expansions in pediatric and critical care markets.
The outlook is high-risk due to persistent losses and negative cash flow, though analyst sentiment is split with a 50% buy rating. Investment potential hinges on the company's ability to achieve profitability and scale its Aquadex platform, while risks include cash burn and competitive pressures in the medical device sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Main Street Capital Corporation
Main Street Capital Corp is an investment firm engaged in providing customized debt and equity financing to lower middle market companies and debt capital to middle market companies. The investment portfolio of the company is typically made to support management buyouts, recapitalizations, growth financings, refinancings and acquisitions of companies that operate in diverse industry sectors. The group invests in secured debt investments, equity investments, warrants and other securities of the lower middle market and middle market companies based in the US. Business is functioned through the U.S region and it derives the majority of the income from the source of fee, commission, and interest.
Read more on MAIN →About Nuwellis Inc
Nuwellis, Inc. is a medical device company focused on developing and commercializing fluid management solutions. The company's primary product is an ultrafiltration system used in hospitals to remove excess fluid from patients with fluid overload, often associated with conditions such as heart and kidney failure. Nuwellis aims to improve patient outcomes and reduce healthcare costs through its specialized, innovative therapies.
Read more on NUWE →
